Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

r meals only if blood glucose levels are elevated. Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion.

On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States, as well as a marketing authorization application to the European Medicines Agency in Europe, for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

LEAD(TM) (Liraglutide Effect and Action in Diabetes) 6 is the first trial to be reported from the phase 3b LEAD(TM) program. Topline results from the LEAD(TM) 6 study were released by Novo Nordisk in a Stock Exchange Announcement on June 6, 2008.

The phase 3a LEAD(TM) program, which comprised the regulatory filing documentation for liraglutide, included trials 1-5. The purpose of the LEAD(TM) program is to compare liraglutide directly against commonly used therapies in type 2 diabetes, except for metformin, with which it is used in combination.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visi
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The laboratory information management systems market is a rapidly ... advancements due to factors such as rising pressure to ... systems, and increasing government support for adoption of HCIT ... in the market focus on technological advancements to further ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... - The Culex quinquefasciatus mosquito poses a ... of elephantiasis-causing worms and encephalitis-inducing viruses. An international team ... and the SIB Swiss Institute of Bioinformatics sequenced its ... articles published in today,s issue of Science, describe results ...
... - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), ... its CYT387 JAK1/JAK2 inhibitor program demonstrating that CYT387 ... which may provide significant clinical advantages. CYT387 is ... study at Mayo Clinic in patients with myelofibrosis. ...
... Inc. - (OTC Bulletin Board: BHRT ) ... of autologous cell therapies for the treatment of cardiovascular ... commitment from Seaside National Bank and Trust for a ... Company,s loan with Bank of America. The loan is ...
Cached Biology Technology:Major disease-vector mosquito reveals the secrets of its immune system 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Bioheart, Inc. Announces Loan to be Assumed by Seaside 2Bioheart, Inc. Announces Loan to be Assumed by Seaside 3
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... Jan. 22, 2015 Infinisource has launched its new NXG ... model. The G2 sets a higher standard for collecting attendance ... management solution. With plug-and-play installation, touch screen interface and seamless ... a robust time collection solution for the small to mid-size ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Apple introduced the fingerprint reading feature with the iPhone ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... biomedical engineer and colleagues have developed a method that, applied ... with increased breast cancer risk the pain and stress of ... lesion. The universal technology will give radiologists greater confidence ... The American Cancer Society recommends that women with certain ...
... an effort to increase understanding of the medical device ... of product development more effectively, researchers at Stanford University ... device development process. Published in the June ... , the model was constructed based on best-practice analysis ...
... Fla. -- The U.S. National Science Foundation (NSF) announced ... of building a multi-decadal time series of Agulhas Current ... Observing System. Led by Principal Investigator, Lisa Beal, ... Marine and Atmospheric Science, the international team will include ...
Cached Biology News:New MRI technique could mean fewer breast biopsies in high-risk women 2Stanford researchers publish comprehensive model for medical device development 2Stanford researchers publish comprehensive model for medical device development 3NSF provides $3.4 million to study climatically important Agulhas Current 2
... in your 35mm dish without transferring ... Chamber has separate openings for solution ... fluctuations of the liquid level in ... from entering the chamber. An adjustable ...
... Five cells (BTI-TN-5B1-4) derived from Trichoplusia ... shown to be capable of expressing ... proteins compared to other insect cells. ... features:- -Rapid doubling time as adherent cultures- Quick ...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
... This kit consists of universal lysis buffer, ... primers for 100 25 l volume PCR ... of Gram negative or positive rod and ... Pneumoniae, Bacillus Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, ...
Biology Products: